https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-01598
Olaparib, Durvalumab, and Tremelimumab in Treating Patients with Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer with BRCA1 or...
olaparibdurvalumabtremelimumabtreatingpatients
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT03660826&r=1
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory...
the combinationtestingolaparibdurvalumabcediranib
https://www.mdpi.com/2072-6694/14/6/1460
Radiotherapy (RT) is a key component of cancer treatment. Although improvements have been made over the years, radioresistance remains a challenge. For this...
taking advantagesenescencepromotingeffectolaparib
https://www.mountsinai.org/clinical-trials/testing-combination-of-olaparib-durvalumab-cediranib-durvalumab-olaparib-capivasertib-cediranib-alone-in-recurrent-refractory-endometrial-cancer-following-earlier-phase-of-study-that-tested-olaparib-cediranib-in-comparison-to-cediranib-alone-olaparib-alone
the combinationtestingolaparibdurvalumabcediranib